title: [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To investigate the incidence and risk factors of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
  
  
  METHODS
  The clinical data of 151 cases of allo-HSCT in 150 patients from Nov 2001 to Jan 2004 was analyzed.
  
  
  RESULTS
  aGVHD was developed in 60 cases (40.2%), including 43 cases with grade I - II and 17 with grade III - IV aGVHD, the mean time of aGVHD development was 21 days (range 1 - 85 days) after allo-HSCT, 35 out of 55 cases achieved complete response (CR) (63.6%). The early survival rate for grade I - II aGVHD was more than 90%, while that for grade III - IV aGVHD was 46%. Nineteen factors possibly correlated with the development of aGVHD were analyzed. The univariate analysis showed that recipient age, donor's sex, recipient's sex, sex and ABO blood group disparity between donor and recipient, diagnosis, the status of disease, the stage of disease, stem cell source, conditioning regimen (TBI/without TBI), CD34(+) cell number, CD3(+) cell number, early engraftment and neutropenic infection were not closely associated with the occurrence of aGVHD (P > 0.05). On the Cox regression model, 2 independent factors for grade I - IV aGVHD were identified:HLA mismatch (RR = 1.681, P < 0.05) and positive surface antigen (HBsAg) (RR = 1.907, P < 0.05). In addition, the univariate analysis showed aGVHD was strongly associated with CMV infection (P < 0.01).
  
  
  CONCLUSIONS
  aGVHD is a common complication after HSCT, HLA mismatch and HBsAg positivity are independent risk factors for aGVHD.
authors.affiliation: Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Chen
authors.forename: Dao-pei
authors.initials: DP
authors.lastname: Lu
authors.forename: Kai-yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Lu-jia
authors.initials: LJ
authors.lastname: Dong
authors.forename: Han-yun
authors.initials: HY
authors.lastname: Ren
authors.forename: Xiao-jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Dai-hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Qian
authors.initials: Q
authors.lastname: Jiang
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Chen
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Yao-chen
authors.initials: YC
authors.lastname: Zhang
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Gao
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology* / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D006680:HLA Antigens; D006514:Hepatitis B Surface Antigens